Immune-related disorders in families of children with inflammatory bowel disease - A prospective cohort study by Sibtain, Alyzée M et al.
RESEARCH Open Access
Immune-related disorders in families of children
with inflammatory bowel disease - A prospective
cohort study
Alyzée M Sibtain
1, Donald Spady
1 and Wael El-Matary
2*
Abstract
Background: The aim of this paper was to examine the prevalence of immune-related disorders in families of
children with inflammatory bowel disease (IBD) compared to those without IBD.
Methods: Children ≤18 years of age presenting to the IBD clinic between September 2007 and August 2009 with
an established diagnosis of IBD were recruited. Age and sex matched controls without IBD were recruited. The
study was a single-centre prospective cohort study. Outcome measures were prevalence of immune-based/
inflammatory diseases in families of both patients and controls.
Results: One hundred and eight children in each group were recruited. Asthma was the most frequently reported
disease in families of the IBD patients (52.8%) and controls (46.3%). The prevalence of IBD in families of IBD
patients was significantly higher than in those without IBD (OR 2.03, 95% CI 1.04-3.95).
Conclusions: The prevalence of immune-based disorders, as a group, in families of children with IBD was not
significantly higher when compared to children without IBD.
Background
Inflammatory bowel diseases (IBD), Crohn’s disease
(CD) and ulcerative colitis (UC) are considered to be
gastrointestinal luminal diseases of immune-dysregula-
tion [1,2]. It is postulated that, IBD results from dys-
functional luminal epithelial barrier, and facilitated by
an inappropriate innate and acquired immune response
to commensal microorganisms that occur in individuals
with appropriate genetic predisposition and susceptibil-
ity [3,4]. A genome study by Becker et al. demonstrated
the presence of non-random overlapping of susceptibil-
ity loci among autoimmune diseases such as multiple
sclerosis (MS), CD, psoriasis, asthma and type I diabetes
(IDDM) [5]. Furthermore, there is considerable evidence
that other immune-related disorders may be associated
with bronchial asthma and rheumatoid arthritis [6-9].
The aim of this single-centre, hospital-based preva-
lence study was to examine the prevalence of family his-
tory of immune-based diseases among pediatric patients
with IBD compared to those without IBD. We hypothe-
sized that there is an increased prevalence of inflamma-
tory or immune-based disease among children
diagnosed with IBD compared to children without IBD.
Methods
In a single centre cohort prospective study, children ≤18
years of age presenting to the IBD clinic or emergency
room, between September 2007 and August 2009, with
an established diagnosis of IBD based on clinical, radi-
ological and endoscopic evidence [10] were recruited (n
= 108). During the same time, children ≤18 years pre-
senting to the general gastrointestinal clinics with func-
tional problems, gastroesophageal reflux or feeding
problems, were recruited as controls (n = 108). IBD was
excluded in the control group based on clinical, radiolo-
gical, and endoscopy if indicated. Patients and controls
were age and sex-matched. Family history of some
immune-based and inflammatory disorders, including
IBD, celiac, autoimmune thyroid disease (including
Grave’sa n dH a s h i m o t o ’s), rheumatoid arthritis, bron-
chial asthma, autoimmune liver disease, multiple
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patients and controls was collected during clinic visits.
A standardized questionnaire was used for each
immune-based disease. Responses were provided from
adults accompanying patients, most often patient’sp a r -
ents and recorded by the investigators during the inter-
view. First-degree relatives were defined as parents and
siblings of patients, and second-degree relatives were
defined as uncles, aunts, and grandparents. For uncles
and aunts it was clarified that the affected relative was a
genetic relative, rather than related by marriage. All
other relatives such as cousins and great grandparents
were classified as distant relatives.
Measures were taken to reduce recall/interviews bias,
included verification of the history taken during clinic
visits against hospital records and taking family history
every time patients or controls presented to IBD/GI
clinics.
Informed consents were obtained from all participants
after circulating study information sheets.
Ethics
The study protocol was approved by the Health
Research Ethics Board of the University of Alberta,
Edmonton, Canada.
Statistical analysis
Data were analyzed using Stata10
(TM) (Data Analysis
and Statistical Software, Stata Corp, Austin, TX, USA).
Summary statistics were obtained for all variables.
Cross-tabulation analysis was made for all variables
against disease (case/control status) to explore any pos-
sible relationships. An initial conditional logistic regres-
sion model was performed, with disease status (case or
control) as the dependent variable and potential
immune disorders as independent variables. Subse-
quently, only those variables that were significant at p <
0 . 0 5l e v e li nt h ei n i t i a lr e g r e s s i o nm o d e lw e r ei n c l u d e d
in the final model.
Results
Asthma was the most frequently reported disease in
both IBD patients (52.8%) and the control group
(46.3%), as well as when CD (52.5%) and UC (53.1%)
patients were examined separately [Table 1]. The second
most frequently reported immune-mediated disease in
IBD group was IBD (33.3%), followed by autoimmune
thyroid disease and rheumatoid arthritis (31%). When
examined separately (CD and UC), the second most fre-
quently reported immune-mediated disorder in patients
with CD after bronchial asthma was autoimmune thyr-
oid disease (30.5%), followed by rheumatoid arthritis
(28.8%) and IBD (27.1%). In UC patients, the second
most frequently reported immune-mediated disorder
was IBD (40.8%), followed by rheumatoid arthritis
(34.7%) and thyroid disease (32.7%). In the control
group, the second most commonly reported immune-
mediated disease was rheumatoid arthritis (33.3%), fol-
lowed by IBD and thyroid disease (24.1%).
There was no statistically significant difference
observed in the prevalence of immune-mediated diseases
as a group in the family history of patients when com-
pared to children without IBD [Table 2]. However,
when the prevalence of IBD, celiac, thyroid disease,
parathyroid disease, rheumatoid arthritis, bronchial
asthma, autoimmune liver disease, MS, and psoriasis or
vitiligo was examined individually, there was a statisti-
cally significant difference between IBD patients and
controls, specifically in regards to IBD. The prevalence
of IBD in the self-reported family history of IBD patients
Table 1 The Prevalence of immune-related disease in families of patients with IBD vs. controls
Diagnosis
Immune-Mediated Disorder IBD (n = 108) CD (n = 59) UC (n = 49) Control (n = 108)
N% N %N %N %
Total Immune-Mediated 89 82.4 47 79.7 42 85.7 92 85.2
IBD 36 33.3 16 27.1 20 40.8 23 21.3
Celiac 9 8.33 5 8.47 4 8.16 8 7.14
IDDM 30 27.8 16 27.1 14 28.6 26 24.1
Thyroid 34 31.5 18 30.5 16 32.7 45 24.1
Parathyroid 2 1.85 1 1.69 1 2.04 1 0.93
Skin 19 17.6 12 20.3 7 14.3 23 21.3
Joint 34 31.5 17 28.8 17 34.7 36 33.3
Asthma 57 52.8 31 52.5 26 53.1 50 46.3
MS 8 7.41 3 5.08 5 10.2 9 8.33
Liver 2 1.85 1 1.69 1 2.04 4 3.7
Abbreviations:
IBD inflammatory bowel disease, CD Crohn’s disease, UC ulcerative colitis, MS multiple sclerosis, IDDM insulin-dependent diabetes mellitus
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children without IBD (OR 2.03, 95% CI 1.04-3.95) and
the difference becomes higher in families with UC
patients (OR 5.3, 95% CI 1.5-18.67)
No statistically significant difference was observed in
the prevalence of any of the other individually-examined
immune-related diseases in families of children with
IBD when compared to children without IBD.
The IBD patients were then categorized based on their
diagnosis of CD or UC. There was no statistically signif-
icant difference in the prevalence of immune-mediated
diseases as a group in families of children with UC or
CD when compared to children without IBD.
Discussion
Over 30% of older school children in Saskatchewan had
wheezing in 12 months prior to a survey that was pub-
lished in 1999 [11]. This prevalence of asthma in
Canada is rising [12]. Asthma was the most frequently
reported disease in families of children with IBD, similar
to those without IBD. Interestingly, some reports indi-
cated a higher prevalence of irritable bowel syndrome (a
functional disorder) among young asthmatics [13].
Rheumatoid arthritis was the second most common
disorder followed by IBD. This finding is consistent with
results from previous studies examining co-morbid con-
ditions among IBD patient [7,14,15]. In a cross-sectional
study from Northern California, Weng et al identified
asthma, rheumatoid arthritis and MS to be the most
common co-morbidities among IBD patients, and sug-
gested genetic linkage of immune-mediated diseases
[16]. Thus, it is not unreasonable to suggest that these
common co-morbidities as well as IBD may also be
more common in families of pediatric patients with IBD.
The IBD occurrence in family of control group 24.1%.
The prevalence of IBD worldwide is approximately 396/
100,000 in a standard population [15]. This discrepancy
between the prevalence in the control group and the
standardized population may be due to the smaller sam-
ple size. Another explanation is the fact that the control
group was recruited from patients with functional gas-
trointestinal problems rather than from general
population.
T h ep r e v a l e n c eo fs e l f - r e p o rted immune-based disor-
ders, as a group, in families of children with IBD was
not significantly higher when compared to children
without IBD. The relationship between autoimmune dis-
eases and IBD has been examined, and several studies
have shown an association between IBD and a positive
family history specifically of MS, rheumatoid arthritis,
and ankylosing spondylitis [16-18].
There was, on the other hand, a significantly higher
prevalence of IBD in families of children with IBD, espe-
cially in children with UC compared to those without
IBD. This finding is consistent with previous studies
demonstrating a familial aspect of IBD [9,15,19]. A
cohort study from six pediatric centres in the United
States by Heyman et al reported a positive family history
of IBD to be more common in UC patients [20]. How-
ever, there was not a significantly higher prevalence of
IBD in families of children with CD. This is surprising,
as CD is known to have a significant familial component
as shown by genetic and population studies [8,19].
Nonetheless, a recent study by Hemminki et al.u s i n g
The Multi-generation Register in Sweden demonstrated
that, though present, concordant familial risks for both
UC and CD were lower than previously cited [17].
The potential limitation of recall bias needs to be con-
sidered. Though patients were asked specifically about
bronchial asthma, there are other types of wheezy chest
syndromes that can be confusing. This may explain why
asthma was not only the most commonly reported
Table 2 Calculated statistical difference in the family history of immune-related disease in children with IBD
IBD CD UC
Immune-Mediated Disease Odds Ratio 95% CI p-value Odds Ratio 95% CI p-value Odds Ratio 95% CI p-value
Total Immune-Mediated Disease 0.82 0.40 1.67 0.71 0.90 0.37 2.20 1 0.68 0.21 2.21 0.76
IBD 2.03 1.04 3.95 <0.05 0.87 0.31 2.42 0.79 5.30 1.50 18.67 <0.05
Celiac 0.91 0.28 2.94 0.87 3.27 0.28 38.42 0.35 1.49 0.20 11.21 0.7
IDDM 1.37 0.69 2.72 0.37 1.63 0.60 4.47 0.34 1.95 0.58 6.60 0.28
Thyroid 0.57 0.29 1.07 0.08 0.71 0.30 1.70 0.44 0.29 0.08 1.023 0.05
Parathyroid 1.56 0.10 24.36 0.75 0.15 0.002 9.61 0.38 0 0 3.86 0.99
Skin 0.76 0.35 1.61 0.48 0.81 0.31 2.26 0.71 0.53 0.13 2.10 0.37
Joint 0.88 0.46 1.68 0.69 0.79 0.31 2.02 0.62 1.38 0.42 4.54 0.59
Asthma 1.32 0.75 2.30 0.34 1.84 0.87 3.89 0.11 1.08 0.34 3.37 0.9
MS 0.887 0.28 2.71 0.81 1.47 0.23 9.41 0.61 0.60 0.11 3.36 0.56
Liver 0.70 0.09 5.35 0.73 2.64 0.08 86.32 0.59 0.33 0.01 7.98 0.49
Abbreviations:
IBD inflammatory bowel disease, CD Crohn’s disease, UC ulcerative colitis, MS multiple sclerosis, IDDM insulin-dependent diabetes mellitus
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trol group family histories, but also why there was no a
significant difference in its prevalence between the two
groups.
Measures taken to reduce recall/interviews bias,
including verification of history taken against hospital
records and taking family history very time patients or
controls were presented to IBD/GI clinics.
Another limitation is that the control group was a
group of children with functional gastrointestinal disor-
ders like irritable bowel syndrome. It is better to recruit
a control group with no gastrointestinal symptoms but
there is no evidence to suggest that inflammatory bowel
diseases are more prevalent in relatives of patients with
functional gastrointestinal problems.
The presence of a significantly increased prevalence of
positive family history of IBD in patients with IBD lends
further support to the exploration of family history
when determining the direction of investigations and
diagnosis in children presenting with symptoms of IBD,
as well as future screening and follow up is warranted.
Conclusions
The present study supports the available evidence docu-
menting a significantly increased prevalence of positive
family history of IBD, among pediatric IBD patients
compared to children without IBD. However, the preva-
lence of self-reported immune-based disorders, as a
group, in families of children with IBD was not signifi-
cantly higher when compared to children without IBD.
Abbreviations
IBD:inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis;
MS: multiple sclerosis; IDDM: insulin-dependent diabetes mellitus.
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